Serum hepcidin levels related to interlukin-6 in patients with acute myeloid leukemia before and after treatment
BACKGROUND: Acute myeloid leukemia (AML) is a heterogeneous malignant disease of hematopoietic tissue. It is characterized by accumulation of abnormal blast cells mainly in bone marrow. Hepcidin is a small bioactive peptide hormone produced in many tissues mainly by the liver, macrophage, and adipoc...
Main Authors: | Khitam Abdulwahhab Ali, Hiba Ammar Mohammad, Alaadin Sahham Naji, Alaa Fadhil Alwan |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2022-01-01
|
Series: | Iraqi Journal of Hematology |
Subjects: | |
Online Access: | http://www.ijhonline.org/article.asp?issn=2072-8069;year=2022;volume=11;issue=1;spage=76;epage=82;aulast=Ali |
Similar Items
-
Evaluation of the Safety of Imatinib Mesylate in 200 Iraqi Patients with Chronic Myeloid Leukemia in the Chronic Phase: Single-Center Study
by: Bassam Francis Matti, et al.
Published: (2013-12-01) -
Pathophysiology of iron and hepcidin metabolism: research perspectives in rheumatolog
by: A. M. Lila, et al.
Published: (2022-11-01) -
Hepcidin and inflammation associated with iron deficiency in childhood obesity - A systematic review
by: Pedro Ferro Berton, et al.
Published: (2024-03-01) -
What’s New in the Classification, Diagnosis and Therapy of Myeloid Leukemias
by: Marco Pizzi, et al.
Published: (2023-03-01) -
Outcome of imatinib mesylate in women with child-bearing age diagnosed with chronic myeloid leukemia
by: Alaa Fadhil Alwan, et al.
Published: (2021-01-01)